RB reports 14% like-for-like growth at Health
Πέμπτη 29 Οκτ 2015
RB said its Health division had recorded sales up by 14% on a like-for-like basis in the third quarter of 2015. Chief executive officer Rakesh Kapoor described the increase as "beyond the range of outperformance".
Kapoor said RB was focusing the organisation's resources, passion and energy on the Health division. We are "innovating hard", "investing in go-to-market" and "investing in healthcare professional programmes", he added.

"I have always said that when you focus your energy, your passion, your investment and your resources, you have a great chance of winning," remarked Kapoor.

RB – formerly known as Reckitt Benckiser – said the Health division had delivered "broad-based" growth across its portfolio in both the third quarter and first nine months of 2015.

Good growth from Scholl/Amopé

The Scholl/Amopé footcare franchise had delivered "good growth", added RB, thanks to the Velvet Smooth Express Pedi, the GelActiv insoles, and the sell-in impact of the new Velvet Smooth Electronic Nail Care System in the US and a number of countries in Europe.

The new Velvet Smooth Electronic Nail Care System is designed to provide people with "a complete professional pedicure in the comfort of their home". A strapline on the packaging promises the product will give "healthier looking shiny nails, effortlessly".

RB said the Nurofen, Strepsils and Durex brands had also put in "good performances". Nurofen pain relievers had benefited from "consumer-education programmes plus an improved go-to-market model in Russia", while Strepsils sore-throat products had been boosted by the launch of Strefen Direct Spray. The company added that there had been a "strong sell-in ahead of the flu season in Russia".

Response to generic versions of Mucinex

RB noted that the US Food and Drug Administration (FDA) had recently approved generic versions of the D, DM and SE Max variants of Mucinex cough and cold medicines. Kapoor said RB would continue to respond with innovations such as the new Mucinex Liquid Gels.

Worldwide sales at RB's Health division rose by 6% as reported to £739 million (US$1.13 billion) in the third quarter of 2015. Sales increased by 6% at constant currencies and by 14% on a like-for-like basis.

The Health division accounted for 33.7% of RB's worldwide sales in the third quarter of 2015, which fell by 1% as reported to £2.20 billion. Sales were up by 6% at constant exchange rates and by 7% on a like-for-like basis.

Commenting on the 7% like-for-like growth, Kapoor said RB's "strategy for growth and outperformance – focused on powermarkets and powerbrands – continues to deliver".

RB continued to achieve broad-based growth throughout its Europe and North America (ENA) powermarkets, said Kapoor, as well as double-digit growth in the Developing Markets (DvM) region. He added that RB's Health and Hygiene brands had achieved an "excellent" quarter, driven by innovations and continued penetration-building programmes.

Uncertainty and volatility in certain markets

Kapoor noted that RB "continues to see uncertainty and volatility in certain markets" and "competitive conditions remain intense".

Commenting on Russia, Kapoor said RB had recorded another good quarter thanks to pricing and an improved go-to-market model in consumer health. He remarked that the "current market and currency issues in Russia continue to make the future difficult to predict".

Mixed picture in developing markets

Looking at the DvM region, Kapoor said RB continued to see a "mixed picture". Conditions in India, the Middle East and Turkey were "positive", he said, but South-East Asia and Latin America remained "challenging".

The company's Hygiene division, which includes the Dettol, Lysol and Veet brands, recorded sales down by 3% as reported at £865 million.

Sales at the Home division were down by 5% as reported to £444 million.

On 23 December 2014, RB demerged its pharmaceuticals business allowing the group to "focus on its core strategy to be a global leader in consumer health and hygiene".

Like-for-like growth excludes the impact of changes in exchange rates, acquisitions, disposals and discontinuations.

Πηγή:  OTC Tool Box

Σχετικά Άρθρα

Κανένα σχόλιο... κάνετε ένα δικό σας σχόλιο

Κάνετε Login για να σχολιάσετε το άρθρο